A selection of experts have highlighted one key hurdle the market should brace for: data management with the EU UDI regime. Due to this area being expected to
differ from the FDA’s GUDID process quite sharply in some places. With the MDR due to come into effect in a few years time, Pharma IQ gains insight on the forecasted data complexities attached to the EU’s UDI gameplan.
Please note: That all fields marked with an asterisk (*) are required.
*Processing your payment may take a moment. Please click submit payment only once, and do not refresh this page. Doing so may result in your credit card being charged more than once.
Your experience on this site will be improved by allowing cookies.